David Raiser

CEO and Co-Founder

David is head of strategy and business development at Aldatu. Prior to founding Aldatu, David worked in biotech and university technology transfer, and led a course on Healthcare Commercialization and Innovation at Harvard Medical School.

David hold Ph.D in Genetics from Harvard Medical School and holds a BS in Biology and BA in Music from the University of Richmond.

Iain MacLeod

CSO and Co-Founder

Iain is responsible for leading the advancement of Aldatu’s pathogen and drug resistance diagnostic technology in addition to guiding the company’s global health strategy. Iain maintains an academic appointment at the Harvard School of Public Health AIDS Initiative.

He undertook his post-doctoral training at the Harvard School of Public Health, and the Botswana-Harvard AIDS Institute in Gaborone, Botswana, where he focused on HIV drug resistance.

Iain holds a Ph.D. in Pathology – specializing in molecular virology – from the University of Cambridge (2008), an LL.M. in International Law, and a B.Sc. in Virology from the University of Glasgow.

Maria Denaro

Technology Specialist

Maria joined Aldatu Biosciences in 2015 as Technology Specialist, taking on the development of multiplex PANDAA assays and daily lab management with earnest. She has many years experience as a BioTech professional in the fields of xenotransplantation and gene therapy.

Prior to joining Aldatu, Maria was Technical Specialist in qPCR at bluebirdbio, Inc. She received a Bachelor of Science degree from Yale University – Go Bulldogs!

Jarukit (Ed) Long

Technology Specialist

Jarukit joined Aldatu Biosciences in 2016 and is responsible for optimizing PANDAA for HIV diagnostics. Prior to joining Aldatu, Jarukit spent his time at the University of Massachusetts Medical School studying and developing high-throughput sequencing methods to understand the required genetic pathways for Mycobacterium tuberculosis survival during infection.

Jarukit earned his PhD in microbiology at the University of Massachusetts Amherst and is a recipient of the Ruth L. Kirschstein National Research Service Award (NRSA) postdoctoral fellowship.

Nicholas Renzette

Technology Specialist

Nick joined Aldatu Biosciences in 2016, working to increase the sensitivity of PANDAA diagnostic assays. Prior to joining Aldatu, Nick was an Instructor at the University of Massachusetts Medical School with a focus on drug resistance evolution of human viral pathogens.

Nick received his Ph.D. in molecular biology from the University of Massachusetts – Amherst and is the recipient of several awards, including the Curtis B. Thorne award for outstanding graduate research and a Ruth L. Kirschstein National Research Service Award (NRSA) postdoctoral fellowship.

Christopher Rowley


Chris is an infectious disease physician at the Beth Israel Deaconess Medical Center in Boston and serves as a consultant for Aldatu’s pathogen detection and drug resistance diagnostic technology.

He is an Assistant Professor of Medicine at Harvard Medical School and a Research Associate at the Harvard School of Public Health. He works with the Botswana-Harvard AIDS Institute in Gaborone, Botswana, where he conducts research focused on HIV drug resistance in southern Africa.

Chris earned his MPH from the Harvard School of Public Health, his MD degree from SUNY Downstate, and a BA in Government/Pre-professional Studies from the University of Notre Dame.

Mark Wainberg

PhD  |  Professor – McGill University AIDS Centre

Prof. Mark A. Wainberg is head of AIDS research at the Lady Davis Institute for Medical Research (LDI), Director of the McGill University AIDS Centre located at the LDI, and Professor of Medicine and of Microbiology and Immunology at McGill University in Montreal. He is an internationally recognized scientist in the field of HIV/AIDS, who served as President of the International AIDS Society between 1998 and 2000 with responsibilities that included organizating the XIIIth International Congress on AIDS in Durban, South Africa in 2000. Dr. Wainberg is proud of the role that he played in choosing South Africa as a venue for this congress, which had an important impact on the issue of access to anti-HIV drugs in developing countries.

He is well-known for his initial identification of 3TC as an anti-viral drug, in collaboration with BioChem Pharma Inc, in 1989, as well as for multiple contributions to the field of HIV drug resistance. His laboratory continues to work in the fields of drug resistance and drug development. As well, Dr. Wainberg has turned his attention to novel concepts in the prevention of HIV infection in developing countries, such as vaginal microbicides and pre-exposure prophylaxis. He was Co-Chair of the XVIth International AIDS Conference that took place in Toronto in 2006. Dr. Wainberg is a member of numerous international advisory committees in the field of AIDS.

Among other distinctions, he is a fellow of the Royal Society of Canada, an Officer of the Order of Canada, an officer of the Ordre National du Québec, an honorary fellow of the Royal College of Physicians and Surgeons of Canada, and a Chevalier in the Legion d’Honneur of France.

Mickey Urdea

PhD  |  Founder and Partner – Halteres Associates

Dr. Urdea is Founder and Partner for Halteres Associates. He also founded and served as Chief Executive Officer of Tethys Bioscience, a proteomics-based diagnostics company that has been involved in the prevention of type-2 diabetes (assets acquired by HDL), and was CEO of Quantum Dots Corporation (assets acquired by Life Technologies).

Additionally, Dr. Urdea is a founder and the Chairman of Catalysis Foundation for Health (CFH), a non-profit organization addressing gaps in global healthcare caused by inefficiencies in disease diagnosis and monitoring; CFH is developing potential biomarkers for tuberculosis bacterial load with a grant for the Bill & Melinda Gates Foundation.

Dr. Urdea is a member of the University of California at San Francisco Leadership Council for Global Health. He serves as a consultant to the life sciences industry and is on the scientific advisory boards and boards of directors of a number of biotechnology and diagnostics companies.

Prior to his current activities, Dr. Urdea founded the Nucleic Acid Diagnostics business at Chiron Corporation, where he pioneered viral load assays for the human hepatitis B, hepatitis C and immunodeficiency viruses; his team introduced the first commercial viral load assays for all three viruses. Dr. Urdea also headed the Oncology Diagnostics business unit at Chiron. He then became business head of the Molecular Diagnostics group and Chief Scientific Officer at Bayer Diagnostics. He has served as an advisor to the Bill & Melinda Gates Foundation for over ten years. Dr. Urdea is an author on over 200 peer-reviewed scientific publications and has more than 125 issued and pending patents.

He received his BS in Biology and Chemistry from Northern Arizona University, his PhD in Biochemistry from Washington State University, and had an NIH postdoctoral fellowship at the University of California at San Francisco.